Hoge Stephen sold $11.7M of MRNA

WHO approved two experimental Ebola vaccines for trials: ChAdOx1 BDBV (Oxford/Serum Institute) and mRNA-1469 (Moderna). They target the Bundibugyo strain, with over 5,300 deaths reported in Africa. Trials led by Congo's National Institute for Biomedical Research, with WHO support.

Moderna (MRNA) announced that the WHO recommended its Ebola vaccine, mRNA-1469, for a Phase 2/3 trial in the Democratic Republic of the Congo. The efficacy study, named Tumaini, has begun.

Moderna (MRNA) shares rose 8% after early data showed its experimental multiple myeloma therapy, mRNA-2808, had four confirmed responses among 11 heavily pretreated patients. The therapy aims to produce three cancer drugs simultaneously, though it is years away from competing with established treatments from Johnson & Johnson (JNJ), Pfizer (PFE), and Regeneron (REGN). The company reports third-quarter results on Friday.

Moderna's mRNA-1469 vaccine candidate for Bundibugyo ebolavirus (BDBV) has been recommended by the WHO to advance to a Phase 2/3 study in the DRC, following encouraging Phase 1 results. The study, supported by CEPI, aims to evaluate the vaccine's efficacy in protecting against BDBV. Moderna's CEO highlighted the potential of mRNA technology in rapidly developing vaccines for emerging infectious diseases.

Moderna's mRNA-1469 vaccine candidate for Bundibugyo virus disease has been recommended for a Phase 2/3 study in the DRC, pending regulatory approval. The recommendation follows encouraging preclinical and Phase 1 data. Moderna is collaborating with CEPI and other partners to support rapid access if the vaccine proves effective.

Moderna (MRNA) announced initial Phase 1/2 clinical data for mRNA-2808, a multiplexed mRNA therapeutic for relapsed or refractory multiple myeloma, will be presented at the 2026 ASH Annual Meeting. Four confirmed responses were observed in 11 evaluable patients, with no dose-limiting toxicities. The company expects to present updated data in December.